Our Pricing

Clinical Evidence: How Wegovy Works for Weight Loss

Understanding how Wegovy works for weight loss requires examining the clinical mechanism behind semaglutide and the robust trial evidence supporting its use. At Cured Pharmacy, our UK-registered clinical team prescribes Wegovy based on MHRA-approved protocols, with transparent pricing from £79.00 and comprehensive patient support throughout your treatment journey.

The Clinical Mechanism: How Wegovy Works in Your Body

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your intestines produce after eating [1]. When you inject Wegovy once weekly, semaglutide binds to GLP-1 receptors in multiple areas: the pancreas, where it enhances insulin secretion and suppresses glucagon; the stomach, where it slows gastric emptying; and crucially, the hypothalamus in your brain, where it reduces appetite and food cravings [1][2].

This multi-target approach explains why Wegovy produces more substantial weight loss than older treatments. By acting on brain regions that control hunger and satiety, semaglutide fundamentally alters your relationship with food rather than simply blocking fat absorption or providing temporary appetite suppression [2]. Patients typically report feeling satisfied with smaller portions and experiencing fewer intrusive thoughts about food within the first few weeks of treatment.

The medication's extended half-life of approximately one week allows for once-weekly dosing, maintaining steady therapeutic levels that provide consistent appetite control throughout the seven-day period [1]. This pharmacokinetic profile represents a significant advance over daily injectable GLP-1 treatments, improving adherence and patient satisfaction.

STEP Trial Results: Clinical Evidence for Wegovy Weight Loss

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme provides the most comprehensive evidence for how Wegovy works for weight loss in real-world populations [2]. In the landmark STEP 1 trial, adults with obesity who received once-weekly semaglutide 2.4mg achieved an average weight reduction of 14.9% over 68 weeks, compared to just 2.4% in the placebo group [2].

More impressively, 86.4% of participants on Wegovy achieved at least 5% weight loss — the threshold associated with meaningful metabolic improvements — whilst 69.1% achieved at least 10% weight loss and 50.5% reached 15% or greater weight reduction [2]. These results significantly exceeded previous pharmacological weight loss interventions and approached outcomes typically seen only with bariatric surgery.

The STEP 2 trial specifically examined semaglutide in patients with type 2 diabetes, demonstrating an average 9.6% weight loss alongside improvements in glycaemic control [3]. This dual benefit makes Wegovy particularly valuable for patients managing both obesity and metabolic complications, though at Cured Pharmacy we prescribe it specifically for weight management in accordance with its UK licence.

Long-Term Weight Maintenance Evidence

The STEP 4 trial addressed a critical question: what happens when you stop taking Wegovy? Participants who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the subsequent year, whilst those who continued treatment maintained their weight loss [4]. This finding underscores that Wegovy works as a long-term treatment for chronic weight management rather than a short-term intervention, requiring ongoing prescription under clinical supervision.

How Wegovy Compares to Other Weight Loss Treatments

When patients ask how Wegovy works compared to alternatives, the distinction lies primarily in receptor selectivity and clinical outcomes. Saxenda contains liraglutide, an earlier-generation GLP-1 agonist requiring daily injections and producing average weight loss of 8% in clinical trials [5]. Wegovy's once-weekly dosing and superior efficacy profile make it the preferred first-line GLP-1 treatment for most patients at Cured Pharmacy, subject to prescriber assessment.

Oral treatments like Orlistat and Mysimba work through entirely different mechanisms — fat absorption blocking and combined opioid-dopamine modulation respectively — and produce more modest weight loss averaging 3-5% [6]. These may suit patients who prefer oral medication or have contraindications to injectable treatments, but they lack the appetite-regulating brain effects that make Wegovy particularly effective.

The newest class of dual GIP/GLP-1 receptor agonists shows even greater efficacy in trials, but Wegovy remains the most extensively studied and widely prescribed injectable weight loss medication in the UK. Our superintendent pharmacist Tarun Kumar and clinical team assess each patient individually to determine the most appropriate treatment based on medical history, weight loss goals, and personal preferences.

What to Expect: Wegovy Dosing Schedule and Timeline

Understanding how Wegovy works requires knowing the gradual dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss [1]. Treatment begins with 0.25mg once weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly by week 17.

Most patients notice appetite reduction within the first two weeks, even at the lowest starter dose. Weight loss typically becomes apparent from week 4-8, with the rate of loss accelerating as you reach higher doses. Clinical trials showed that maximum weight loss occurred around 60-68 weeks, though many patients achieve their goals earlier [2].

At Cured Pharmacy, we provide Wegovy pens pre-filled with the correct dose for each stage of your treatment. Your UK prescriber will issue prescriptions covering the appropriate escalation schedule, and our pharmacy team coordinates delivery timing to ensure you never miss a dose. All prescription medications require ongoing clinical assessment to monitor efficacy and tolerability.

Injection Technique and Administration

Wegovy is administered subcutaneously (under the skin) in the abdomen, thigh, or upper arm using a simple pre-filled pen device. The injection takes seconds and uses a fine needle that most patients find comfortable. Rotating injection sites and injecting on the same day each week optimises absorption and helps establish a consistent routine that supports long-term adherence.

Managing Side Effects: What the Clinical Evidence Shows

The most common side effects reported in STEP trials were gastrointestinal: nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) [2]. These symptoms were generally mild to moderate, occurred predominantly during dose escalation, and diminished over time as patients developed tolerance to semaglutide.

The gradual dose titration schedule exists specifically to allow your digestive system to adapt to how Wegovy works. Starting with smaller doses and increasing slowly over four months significantly reduces the intensity and duration of GI symptoms compared to starting at full therapeutic doses. Most patients who experience nausea find it manageable with simple dietary modifications: eating smaller meals, avoiding high-fat foods, and staying well-hydrated.

Serious adverse events were rare in clinical trials, occurring at similar rates in semaglutide and placebo groups [2]. However, Wegovy carries contraindications including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. Your UK prescriber at Cured Pharmacy will screen for these conditions during your clinical assessment before approving treatment.

Accessing Wegovy Through Cured Pharmacy: Clinical Assessment and Pricing

Wegovy is a prescription-only medication in the UK, requiring clinical assessment by a registered prescriber before dispensing. At Cured Pharmacy, we've streamlined this process with a comprehensive online consultation that takes under three minutes to complete. Our UK-registered clinical team reviews your medical history, current medications, and weight loss goals to determine if Wegovy is appropriate and safe for you.

We maintain transparent upfront pricing with Wegovy available from £79.00 — significantly lower than typical market rates whilst maintaining our commitment to genuine UK-licensed medicines only. This price includes your medication, clinical assessment, and discreet delivery to your door. Unlike some services that hide costs until after consultation, we display exact pricing before you begin your assessment.

Once approved, your prescription is fulfilled by our GPhC-registered pharmacy (registration number 9012511) under the supervision of superintendent pharmacist Tarun Kumar (GPhC 2233073). We dispense only authentic Wegovy pens sourced through licensed UK pharmaceutical wholesalers, never grey-market imports. Your medication arrives in 100% discreet packaging with no external indication of contents, and our clinical team remains available at (+44) 116 4646009 for any questions throughout your treatment journey.

Ongoing Monitoring and Support

Successful weight loss with Wegovy requires more than just injections — it involves ongoing clinical monitoring to assess progress, manage any side effects, and adjust treatment as needed. Your prescriber will schedule regular reviews to evaluate weight loss trajectory, discuss any concerns, and ensure the medication continues to work effectively. This supervised approach aligns with MHRA guidance and NICE recommendations for safe, sustainable weight management.

Scientific References

1. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
5. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
6. Khera, R., et al. (2016). Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 315(22), 2424–2434. https://doi.org/10.1001/jama.2016.7602

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Clinical trial results represent average outcomes and individual results may vary.